GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of bile ducts and
occurs proximal to the segmental biliary ducts. ICC is highly aggressive, long-term survival
only can be achieved in patients with R0 surgical resection. Large diameter of tumor,
multiple tumors, preoperative carbohydrate antigen(CA)19-9 elevated, tumors invaded adjacent
blood vessels and preoperative radiology hints suspected regional lymph node metastasis were
considered as high-risk factors of recurrence in the previous study. Chemotherapy can trigger
antigen release and induces strong anti-tumor effects of T cells due to cytotoxic cell death.
Immune checkpoint inhibitors can relieve tumor immunosuppressive microenvironment. Hence, we
aim to investigate objective response rate and R0 resection rate and survival rate of
patients with high-risk factors of recurrence who receives Tislelizumab combined with GEMOX
regimen(GOT) as a neoadjuvant therapy.